Will SGK public coverage with Allianz Sigorta, Anadolu Sigorta, and Acibadem Sigorta employer plans cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Anktiva is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by TITCK?

The TITCK named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; TITCK review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Turkish-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Turkish Medical Association (TTB) and the Ministry of Health licensing directorate verifies the active license; the TITCK application records both the prescribing physician and the dispensing facility.

Can I receive Anktiva at home?

The dispensing facility must be Turkish-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative quote provided at intake. Delivered quote within 24h.Get my quote

Anktiva access in Turkey: the TITCK named-patient pathway

How patients in the Republic of Turkiye legally obtain Anktiva (nogapendekin alfa inbakicept-pmln) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Turkey access Anktiva (nogapendekin alfa inbakicept-pmln) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumours, in adults, given with BCG through the TITCK named-patient pathway, a the Turkish Medicines and Medical Devices Agency (Turkiye Ilac ve Tibbi Cihaz Kurumu)-administered mechanism that allows a Turkish-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in TRY.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Anktiva reaches patients in Turkey

Anktiva (nogapendekin alfa inbakicept-pmln, an IL-15 receptor superagonist fusion protein from ImmunityBio, FDA-approved 22 April 2024 in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumours) is not currently listed on the TITCK registered-product database at titck.gov.tr/dinamikmodul/43 as of 2026-06-01. Access is administered under Additional Article 7 of Law No. 1262 on Pharmaceutical and Medical Preparations through the personal-treatment pathway codified in TITCK's Yurt Disindan Ilac Temini ve Kullanimi Kilavuzu (Guideline on Provision and Use of Medicines from Abroad), Revision 14 dated 29 August 2024, available at portal.aifd.org.tr. The treating urologic oncologist files the epicrisis, scientific justification, prescription, and supporting literature with the TITCK Sahsi Tedavide Kullanilacak Ilaclarin Degerlendirilmesi Komisyonu (Commission for Evaluation of Medicines in Personal Treatment). For Anktiva specifically, the file must reference cystoscopy and biopsy confirmation of high-grade non-muscle invasive bladder cancer with carcinoma in situ, documented BCG-unresponsive disease per the FDA definition (persistent or recurrent CIS within 12 months of adequate BCG induction plus maintenance per the QUILT-3.032 trial enrolment criteria, NCT03022825), the planned Anktiva plus BCG intravesical induction and maintenance schedule, the cystoscopic surveillance plan, and patient counselling on radical cystectomy as the alternative. On clinical approval the dossier routes to USHAS at ushas.com.tr or to the Turkish Pharmacists Association (TEB) at teb.org.tr as the named-patient import channel. Foreign-sourced product registration on the National Drug Tracking System (Ilac Takip Sistemi, ITS) was made mandatory by Resmi Gazete regulation as reported at aa.com.tr, adding a track-and-trace step at receipt.

Where Anktiva is dispensed in Turkey

Anktiva is administered as intravesical instillation in combination with intravesical BCG in an outpatient urology clinic or day-case unit, with cystoscopy at six and twelve months for response assessment per the FDA-approved monitoring schedule. The dispensing site must hold 2 to 8 degrees Celsius refrigerated storage with continuous temperature monitoring and a urology service with cystoscopy and intravesical-therapy capability. The Turkish institutions with adult urology oncology capability appropriate to BCG-unresponsive non-muscle invasive bladder cancer management include Hacettepe University Adult Urology and Urologic Oncology in Ankara at hastane.hacettepe.edu.tr (ESMO Designated Centre of Integrated Oncology); Ankara University Ibni Sina Hospital Department of Urology, the longstanding academic urology programme of the Ankara University Faculty of Medicine; Istanbul University Istanbul Faculty of Medicine (Capa) Department of Urology; Istanbul University-Cerrahpasa Cerrahpasa Medical Faculty Hospital Department of Urology; Marmara University Pendik Training and Research Hospital Department of Urology in Istanbul; Acibadem Maslak, Altunizade, and Atakent Hospitals Urology departments accessible at acibademinternational.com; Memorial Sisli and Bahcelievler Hospitals Urology departments in Istanbul; and Anadolu Medical Center (Johns Hopkins Medicine affiliate) Urology programme in Kocaeli. Hacettepe and Ankara University Ibni Sina are the centres most frequently cited in Turkish urology reporting for academic-led intravesical bladder-cancer immunotherapy workflows.

What Anktiva costs in Turkey

The US wholesale acquisition cost for Anktiva is approximately USD 89,200 per induction course (six weekly instillations) and approximately USD 245,000 per full first-year course including maintenance instillations per ImmunityBio launch disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Cumulative cost depends on the cystoscopic-response-driven maintenance schedule (continued instillations every three months for the first year then reduced cadence for up to 37 months per the protocol). No public Turkish Lira benchmark for Anktiva on the TITCK pricing tables or in SGK reimbursement publications has been observed as of 2026-06-01; do not estimate. Price snapshot: 2026-06-01. Cost layers above the drug cost include validated cold-chain logistics from the ImmunityBio supplier through the TEB or USHAS channel into the Turkish dispensing centre (2 to 8 degrees Celsius with continuous monitoring), the outpatient urology procedure fee for intravesical instillation, the cystoscopy surveillance fee under hospital tariff, and the Reserve Meds concierge fee itemised separately on every firm quote. Co-administered BCG supply availability is a separate planning constraint and is sourced through the same TEB or USHAS channel. The Central Bank of Turkey TRY/USD spot rate on the snapshot date should be footnoted by the patient's financial controller at the time of any TRY quote conversion; TRY has been volatile across 2021-2024 per Central Bank of Turkey rate history at tcmb.gov.tr.

Funding and access barriers for Anktiva in Turkey

Turkey's Social Security Institution (Sosyal Guvenlik Kurumu, SGK) is the dominant payer for almost all Turkish residents and reimburses named-patient imports under the Saglik Uygulama Tebligi (SUT) section 4.3 framework documented at sgk.gov.tr. Under named-patient personal-treatment use, SGK reimbursement of foreign-sourced medicines is generally available at prices exempt from international reference pricing and mandatory discounts, a posture documented in the Cambridge International Journal of Technology Assessment in Health Care analysis at cambridge.org. For Anktiva, the practical sequence is urology approval at a designated bladder-cancer multidisciplinary clinic, TITCK personal-treatment permit referencing BCG-unresponsive status, and SGK reimbursement decision tied to the prior-BCG documentation. Private supplementary insurers active in this profile include Acibadem Sigorta, Anadolu Sigorta, Allianz Sigorta, AXA Sigorta, Mapfre Sigorta, and Generali; these typically cover patient out-of-pocket exposure at private facilities and are coverage-tier dependent for unlicensed-import intravesical immunotherapy. A structural access constraint specific to Anktiva is the co-administered BCG requirement and periodic global BCG shortages; Turkish urology centres plan BCG supply alongside the Anktiva personal-treatment permit cycle. ImmunityBio US patient assistance programmes do not extend to Turkish residents.

Recent regulatory and access news for Anktiva

TITCK issued Revision 14 of the Yurt Disindan Ilac Temini ve Kullanimi Kilavuzu on 29 August 2024, the operative reference for any current Anktiva personal-treatment file; consolidated PDF at portal.aifd.org.tr. The Anatolian Agency reported the Resmi Gazete regulation making registration of foreign-sourced medicines on the Ilac Takip Sistemi (ITS) mandatory at aa.com.tr, applicable to bladder-cancer intravesical biologics sourced from US manufacturers. TITCK published a clarification statement on Yurt Disindan Ilac Temini following supply and pricing controversies at aa.com.tr. No drug-specific TITCK or SGK bulletin for Anktiva over the last 12 months has been observed as of 2026-06-01.

Where Reserve Meds fits in Anktiva cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace TITCK, and we do not replace your dispensing pharmacy. For Anktiva specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Turkey, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Anktiva case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the TITCK application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Turkish specialty care concentrates at the Acibadem, American Hospital, and Memorial chains in Istanbul, with Hacettepe University Hospital in Ankara serving as the principal academic referral centre; the TITCK named-patient supply pathway is routed through the Turkish Pharmacists Association (TEB) foreign medicines channel.

Next step

If your Turkish physician has prescribed Anktiva and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Anktiva case Or message us on WhatsApp